Q2 EPS Estimates for Flora Growth Lowered by Roth Capital

Flora Growth Corp. (NASDAQ:FLGC) – Analysts at Roth Capital dropped their Q2 2025 earnings per share estimates for shares of Flora Growth in a research note issued to investors on Wednesday, May 14th. Roth Capital analyst W. Kirk now expects that the company will post earnings per share of ($0.06) for the quarter, down from their prior forecast of $0.02. The consensus estimate for Flora Growth’s current full-year earnings is ($0.93) per share. Roth Capital also issued estimates for Flora Growth’s Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.21) EPS.

Flora Growth (NASDAQ:FLGC) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.03). The business had revenue of $11.79 million during the quarter, compared to analysts’ expectations of $14.79 million. Flora Growth had a negative return on equity of 268.17% and a negative net margin of 30.99%.

Flora Growth Stock Up 2.4%

Shares of Flora Growth stock opened at $0.68 on Friday. The stock has a 50-day moving average price of $0.59 and a 200 day moving average price of $0.93. The company has a market cap of $13.13 million, a P/E ratio of -0.69 and a beta of 2.01. The company has a current ratio of 1.02, a quick ratio of 0.64 and a debt-to-equity ratio of 0.43. Flora Growth has a 1 year low of $0.42 and a 1 year high of $2.11.

Institutional Investors Weigh In On Flora Growth

Hedge funds have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Flora Growth in the 4th quarter worth about $43,000. AdvisorShares Investments LLC purchased a new stake in shares of Flora Growth during the 4th quarter worth about $73,000. Finally, Geode Capital Management LLC raised its stake in shares of Flora Growth by 23.3% during the 4th quarter. Geode Capital Management LLC now owns 130,934 shares of the company’s stock worth $135,000 after purchasing an additional 24,713 shares in the last quarter. 36.01% of the stock is owned by hedge funds and other institutional investors.

Flora Growth Company Profile

Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products.